Gerd Burmester, MD

Charité - Universitätsmedizin Berlin
Berlin, Germany

Senior Professor, Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin

1353: Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data

Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): Celltrion: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Chugai: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Gedeon Richter: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing)